Skip to main content
Erschienen in: Annals of Surgical Oncology 1/2023

08.10.2022 | Sarcoma

Prognosis of Patients with Cutaneous Angiosarcoma After Surgical Resection with Curative Intent: Is There a Difference Between the Subtypes?

verfasst von: Sophie J. M. Reijers, MD, Eva A. Huis in ’t Veld, MD, Dirk J. Grünhagen, MD, PhD, Myles J. F. Smith, MB, BCh, BAO, PhD, FRCSI, Tessa M. van Ginhoven, MD, PhD, Frits van Coevorden, MD, PhD, Winette T. A. van der Graaf, MD, PhD, Yvonne Schrage, MD, PhD, Dirk C. Strauss, MD, PhD, Rick L. M. Haas, MD, PhD, Cornelis J. Verhoef, MD, PhD, Andrew J. Hayes, MD, PhD, Winan J. van Houdt, MD, PhD

Erschienen in: Annals of Surgical Oncology | Ausgabe 1/2023

Einloggen, um Zugang zu erhalten

Abstract

Background

The etiology of cutaneous angiosarcoma (cAS) may be idiopathic (I-cAS), or arise secondary to radiotherapy (RT-cAS), in chronic lymphedema (ST-cAS), or related to UV exposure (UV-cAS). The aim of this study was to evaluate oncological outcomes of different cAS subtypes.

Patients and Methods

Non-metastatic cAS patients, treated with surgery for primary disease with curative intent, were retrospectively analyzed for oncological outcome, including local recurrence (LR), distant metastases (DM), and overall survival (OS).

Results

A total of 234 patients were identified; 60 I-cAS, 122 RT-cAS, 9 ST-cAS, and 43 UV-cAS. The majority was female (78%), the median age was 66 years (IQR 57–76 years), the median tumor size was 4.4 cm (IQR 2.5–7.0 cm), and most common site of disease was the breast (59%). Recurrence was identified in 66% (44% LR and/or 41% DM), with a median follow up of 26.5 months (IQR 12–60 months). The 5-year OS was estimated at 50%, LRFS at 47%, and DMFS at 50%. There was no significant difference in LR, DM, or OS between the subtypes. Age < 65 years and administration of radiotherapy (RT) were significantly associated with lower LR rates (HR 0.560, 95% CI 0.3373–0.840, p = 0.005 and HR 0.421, 95% CI 0.225–0.790, p = 0.007, respectively), however no prognostic factors were identified for development of DM. Development of DM, but not LR (p = 0.052), was significantly associated with decreased OS (HR 6.486, 95% CI 2.939–14.318 p < 0.001).

Conclusion

We found no significant difference in oncological outcome between the different cAS subtypes. OS remains relatively poor, and RT is associated with lower LR rates.
Literatur
1.
Zurück zum Zitat NCIN. Soft Tissue Sarcoma; Incidence and survival. Tumor diagnosed in England between 1985-2009. 2012. NCIN. Soft Tissue Sarcoma; Incidence and survival. Tumor diagnosed in England between 1985-2009. 2012.
2.
Zurück zum Zitat Toro JR, Travis LB, Wu HJ, Zhu K, Fletcher CD, Devesa SS. Incidence patterns of soft tissue sarcomas, regardless of primary site, in the surveillance, epidemiology and end results program, 1978–2001: an analysis of 26,758 cases. Int J Cancer. 2006;119(12):2922–30.CrossRef Toro JR, Travis LB, Wu HJ, Zhu K, Fletcher CD, Devesa SS. Incidence patterns of soft tissue sarcomas, regardless of primary site, in the surveillance, epidemiology and end results program, 1978–2001: an analysis of 26,758 cases. Int J Cancer. 2006;119(12):2922–30.CrossRef
3.
Zurück zum Zitat Board WCoTE. Soft Tissue and Bone Tumours. Vol 3. 5 ed2020. Board WCoTE. Soft Tissue and Bone Tumours. Vol 3. 5 ed2020.
4.
Zurück zum Zitat Cao J, Wang J, He C, Fang M. Angiosarcoma: a review of diagnosis and current treatment. Am J Cancer Res. 2019;9(11):2303–13. Cao J, Wang J, He C, Fang M. Angiosarcoma: a review of diagnosis and current treatment. Am J Cancer Res. 2019;9(11):2303–13.
5.
Zurück zum Zitat Depla AL, Scharloo-Karels CH, de Jong MAA, et al. Treatment and prognostic factors of radiation-associated angiosarcoma (RAAS) after primary breast cancer: a systematic review. Eur J Cancer. 2014;50(10):1779–88.CrossRef Depla AL, Scharloo-Karels CH, de Jong MAA, et al. Treatment and prognostic factors of radiation-associated angiosarcoma (RAAS) after primary breast cancer: a systematic review. Eur J Cancer. 2014;50(10):1779–88.CrossRef
6.
Zurück zum Zitat Young RJ, Brown NJ, Reed MW, Hughes D, Woll PJ. Angiosarcoma. Lancet Oncol. 2010;11(10):983–91.CrossRef Young RJ, Brown NJ, Reed MW, Hughes D, Woll PJ. Angiosarcoma. Lancet Oncol. 2010;11(10):983–91.CrossRef
7.
Zurück zum Zitat Painter CA, Jain E, Tomson BN, et al. The Angiosarcoma Project: enabling genomic and clinical discoveries in a rare cancer through patient-partnered research. Nat Med. 2020;26(2):181–7.CrossRef Painter CA, Jain E, Tomson BN, et al. The Angiosarcoma Project: enabling genomic and clinical discoveries in a rare cancer through patient-partnered research. Nat Med. 2020;26(2):181–7.CrossRef
8.
Zurück zum Zitat Shon W, Sukov WR, Jenkins SM, Folpe AL. MYC amplification and overexpression in primary cutaneous angiosarcoma: a fluorescence in-situ hybridization and immunohistochemical study. Mod Pathol. 2014;27(4):509–15.CrossRef Shon W, Sukov WR, Jenkins SM, Folpe AL. MYC amplification and overexpression in primary cutaneous angiosarcoma: a fluorescence in-situ hybridization and immunohistochemical study. Mod Pathol. 2014;27(4):509–15.CrossRef
9.
Zurück zum Zitat Merfeld E, Gabani P, Spraker MB, et al. Clinical outcomes and prognostic features of angiosarcoma: significance of prior radiation therapy. Clin Oncol (R Coll Radiol). 2019;31(4):232–41.CrossRef Merfeld E, Gabani P, Spraker MB, et al. Clinical outcomes and prognostic features of angiosarcoma: significance of prior radiation therapy. Clin Oncol (R Coll Radiol). 2019;31(4):232–41.CrossRef
10.
Zurück zum Zitat Weidema ME, Flucke UE, van der Graaf WTA, et al. Prognostic factors in a large nationwide cohort of histologically confirmed primary and secondary angiosarcomas. Cancers (Basel). 2019;11(11):1780.CrossRef Weidema ME, Flucke UE, van der Graaf WTA, et al. Prognostic factors in a large nationwide cohort of histologically confirmed primary and secondary angiosarcomas. Cancers (Basel). 2019;11(11):1780.CrossRef
11.
Zurück zum Zitat Espejo-Freire AP, Elliott A, Rosenberg A, et al. Genomic landscape of angiosarcoma: a targeted and immunotherapy biomarker analysis. Cancers (Basel). 2021;13(19):4816.CrossRef Espejo-Freire AP, Elliott A, Rosenberg A, et al. Genomic landscape of angiosarcoma: a targeted and immunotherapy biomarker analysis. Cancers (Basel). 2021;13(19):4816.CrossRef
12.
Zurück zum Zitat Wang L, Lao IW, Yu L, Wang J. Clinicopathological features and prognostic factors in angiosarcoma: a retrospective analysis of 200 patients from a single Chinese medical institute. Oncol Lett. 2017;14(5):5370–8. Wang L, Lao IW, Yu L, Wang J. Clinicopathological features and prognostic factors in angiosarcoma: a retrospective analysis of 200 patients from a single Chinese medical institute. Oncol Lett. 2017;14(5):5370–8.
13.
Zurück zum Zitat Buehler D, Rice SR, Moody JS, et al. Angiosarcoma outcomes and prognostic factors: a 25-year single institution experience. Am J Clin Oncol. 2014;37(5):473–9.CrossRef Buehler D, Rice SR, Moody JS, et al. Angiosarcoma outcomes and prognostic factors: a 25-year single institution experience. Am J Clin Oncol. 2014;37(5):473–9.CrossRef
14.
Zurück zum Zitat Fayette J, Martin E, Piperno-Neumann S, et al. Angiosarcomas, a heterogeneous group of sarcomas with specific behavior depending on primary site: a retrospective study of 161 cases. Ann Oncol. 2007;18(12):2030–6.CrossRef Fayette J, Martin E, Piperno-Neumann S, et al. Angiosarcomas, a heterogeneous group of sarcomas with specific behavior depending on primary site: a retrospective study of 161 cases. Ann Oncol. 2007;18(12):2030–6.CrossRef
15.
Zurück zum Zitat Schott I, Liffers ST, Farzaliyev F, et al. Localized angiosarcoma, not one disease: a retrospective single-center study on prognosis depending on the primary site and etiology. Sarcoma. 2021;2021:9960085.CrossRef Schott I, Liffers ST, Farzaliyev F, et al. Localized angiosarcoma, not one disease: a retrospective single-center study on prognosis depending on the primary site and etiology. Sarcoma. 2021;2021:9960085.CrossRef
16.
Zurück zum Zitat Lindet C, Neuville A, Penel N, et al. Localised angiosarcomas: the identification of prognostic factors and analysis of treatment impact. A retrospective analysis from the French Sarcoma Group (GSF/GETO). Eur J Cancer. 2013;49(2):369–76.CrossRef Lindet C, Neuville A, Penel N, et al. Localised angiosarcomas: the identification of prognostic factors and analysis of treatment impact. A retrospective analysis from the French Sarcoma Group (GSF/GETO). Eur J Cancer. 2013;49(2):369–76.CrossRef
17.
Zurück zum Zitat Albores-Saavedra J, Schwartz AM, Henson DE, et al. Cutaneous angiosarcoma. Analysis of 434 cases from the Surveillance, Epidemiology, and End Results Program, 1973–2007. Ann Diagn Pathol. 2011;15(2):93–7.CrossRef Albores-Saavedra J, Schwartz AM, Henson DE, et al. Cutaneous angiosarcoma. Analysis of 434 cases from the Surveillance, Epidemiology, and End Results Program, 1973–2007. Ann Diagn Pathol. 2011;15(2):93–7.CrossRef
18.
Zurück zum Zitat Rouhani P, Fletcher CD, Devesa SS, Toro JR. Cutaneous soft tissue sarcoma incidence patterns in the U.S.: an analysis of 12,114 cases. Cancer. 2008;113(3):616–27.CrossRef Rouhani P, Fletcher CD, Devesa SS, Toro JR. Cutaneous soft tissue sarcoma incidence patterns in the U.S.: an analysis of 12,114 cases. Cancer. 2008;113(3):616–27.CrossRef
19.
Zurück zum Zitat Stewart FW, Treves N. Lymphangiosarcoma in postmastectomy lymphedema; a report of six cases in elephantiasis chirurgica. Cancer. 1948;1(1):64–81.CrossRef Stewart FW, Treves N. Lymphangiosarcoma in postmastectomy lymphedema; a report of six cases in elephantiasis chirurgica. Cancer. 1948;1(1):64–81.CrossRef
20.
Zurück zum Zitat Huis In’t Veld EA, Grunhagen DJ, Verhoef C, et al. Isolated limb perfusion for locally advanced angiosarcoma in extremities: a multi-centre study. Eur J Cancer. 2017;85:114–21.CrossRef Huis In’t Veld EA, Grunhagen DJ, Verhoef C, et al. Isolated limb perfusion for locally advanced angiosarcoma in extremities: a multi-centre study. Eur J Cancer. 2017;85:114–21.CrossRef
21.
Zurück zum Zitat Lans TE, de Wilt JH, van Geel AN, Eggermont AM. Isolated limb perfusion with tumor necrosis factor and melphalan for nonresectable Stewart-Treves lymphangiosarcoma. Ann Surg Oncol. 2002;9(10):1004–9.CrossRef Lans TE, de Wilt JH, van Geel AN, Eggermont AM. Isolated limb perfusion with tumor necrosis factor and melphalan for nonresectable Stewart-Treves lymphangiosarcoma. Ann Surg Oncol. 2002;9(10):1004–9.CrossRef
22.
Zurück zum Zitat Chen TW, Pang A, Puhaindran ME, et al. The treatment landscape of advanced angiosarcoma in Asia-A multi-national collaboration from the Asian Sarcoma Consortium. Cancer Sci. 2021;112(3):1095–104.CrossRef Chen TW, Pang A, Puhaindran ME, et al. The treatment landscape of advanced angiosarcoma in Asia-A multi-national collaboration from the Asian Sarcoma Consortium. Cancer Sci. 2021;112(3):1095–104.CrossRef
23.
Zurück zum Zitat Cassidy RJ, Switchenko JM, Yushak ML, et al. The importance of surgery in scalp angiosarcomas. Surg Oncol. 2018;27(4):A3–8.CrossRef Cassidy RJ, Switchenko JM, Yushak ML, et al. The importance of surgery in scalp angiosarcomas. Surg Oncol. 2018;27(4):A3–8.CrossRef
24.
Zurück zum Zitat Jiang T, Ye Z, Shao T, Luo Y, Wang B. Prognostic nomograms for predicting overall survival and cancer-specific survival in patients with angiosarcoma, a SEER population-based study. Sci Rep. 2022;12(1):3479.CrossRef Jiang T, Ye Z, Shao T, Luo Y, Wang B. Prognostic nomograms for predicting overall survival and cancer-specific survival in patients with angiosarcoma, a SEER population-based study. Sci Rep. 2022;12(1):3479.CrossRef
25.
Zurück zum Zitat Cohen-Hallaleh RB, Smith HG, Smith RC, et al. Radiation induced angiosarcoma of the breast: outcomes from a retrospective case series. Clin Sarcoma Res. 2017;7:15.CrossRef Cohen-Hallaleh RB, Smith HG, Smith RC, et al. Radiation induced angiosarcoma of the breast: outcomes from a retrospective case series. Clin Sarcoma Res. 2017;7:15.CrossRef
26.
Zurück zum Zitat Pawlik TM, Paulino AF, McGinn CJ, et al. Cutaneous angiosarcoma of the scalp: a multidisciplinary approach. Cancer. 2003;98(8):1716–26.CrossRef Pawlik TM, Paulino AF, McGinn CJ, et al. Cutaneous angiosarcoma of the scalp: a multidisciplinary approach. Cancer. 2003;98(8):1716–26.CrossRef
27.
Zurück zum Zitat Kuan CH, Yang HW, Huang HF, et al. Prognostic significance of positive surgical margins for scalp angiosarcoma. J Formos Med Assoc. 2021;120(1 Pt 1):217–25.CrossRef Kuan CH, Yang HW, Huang HF, et al. Prognostic significance of positive surgical margins for scalp angiosarcoma. J Formos Med Assoc. 2021;120(1 Pt 1):217–25.CrossRef
28.
Zurück zum Zitat Jallali N, James S, Searle A, Ghattaura A, Hayes A, Harris P. Surgical management of radiation-induced angiosarcoma after breast conservation therapy. Am J Surg. 2012;203(2):156–61.CrossRef Jallali N, James S, Searle A, Ghattaura A, Hayes A, Harris P. Surgical management of radiation-induced angiosarcoma after breast conservation therapy. Am J Surg. 2012;203(2):156–61.CrossRef
29.
Zurück zum Zitat Farzaliyev F, Hamacher R, Steinau Professor HU, Bertram S, Podleska LE. Secondary angiosarcoma: a fatal complication of chronic lymphedema. J Surg Oncol. 2020;121(1):85–90. Farzaliyev F, Hamacher R, Steinau Professor HU, Bertram S, Podleska LE. Secondary angiosarcoma: a fatal complication of chronic lymphedema. J Surg Oncol. 2020;121(1):85–90.
30.
Zurück zum Zitat Guadagnolo BA, Zagars GK, Araujo D, Ravi V, Shellenberger TD, Sturgis EM. Outcomes after definitive treatment for cutaneous angiosarcoma of the face and scalp. Head Neck. 2011;33(5):661–7.CrossRef Guadagnolo BA, Zagars GK, Araujo D, Ravi V, Shellenberger TD, Sturgis EM. Outcomes after definitive treatment for cutaneous angiosarcoma of the face and scalp. Head Neck. 2011;33(5):661–7.CrossRef
31.
Zurück zum Zitat Sharon CE, Straker RJ, Shannon AB, et al. Neoadjuvant radiation for cutaneous and soft tissue angiosarcoma. J Surg Oncol. 2022;125(3):509–15.CrossRef Sharon CE, Straker RJ, Shannon AB, et al. Neoadjuvant radiation for cutaneous and soft tissue angiosarcoma. J Surg Oncol. 2022;125(3):509–15.CrossRef
32.
Zurück zum Zitat Guram S, Covelli AM, O’Neill AC, et al. Multidisciplinary intervention in radiation-associated angiosarcoma of the breast: patterns of recurrence and response to treatment. Ann Surg Oncol. 2022;29(1):522–32.CrossRef Guram S, Covelli AM, O’Neill AC, et al. Multidisciplinary intervention in radiation-associated angiosarcoma of the breast: patterns of recurrence and response to treatment. Ann Surg Oncol. 2022;29(1):522–32.CrossRef
33.
Zurück zum Zitat Notter M, Stutz E, Thomsen AR, Vaupel P. Radiation-associated angiosarcoma of the breast and chest wall treated with thermography-controlled, contactless wira-hyperthermia and hypofractionated re-irradiation. Cancers (Basel). 2021;13(15):3911.CrossRef Notter M, Stutz E, Thomsen AR, Vaupel P. Radiation-associated angiosarcoma of the breast and chest wall treated with thermography-controlled, contactless wira-hyperthermia and hypofractionated re-irradiation. Cancers (Basel). 2021;13(15):3911.CrossRef
34.
Zurück zum Zitat Molitoris JK, Chhabra A, Snider JW, et al. Intensification of treatment for angiosarcoma of the breast with accelerated hyperfractionated radiation, hyperthermia, and surgical resection. Cureus. 2017;9(6):e1406. Molitoris JK, Chhabra A, Snider JW, et al. Intensification of treatment for angiosarcoma of the breast with accelerated hyperfractionated radiation, hyperthermia, and surgical resection. Cureus. 2017;9(6):e1406.
35.
Zurück zum Zitat de Jong MA, Oldenborg S, Bing Oei S, et al. Reirradiation and hyperthermia for radiation-associated sarcoma. Cancer. 2012;118(1):180–7.CrossRef de Jong MA, Oldenborg S, Bing Oei S, et al. Reirradiation and hyperthermia for radiation-associated sarcoma. Cancer. 2012;118(1):180–7.CrossRef
36.
Zurück zum Zitat Heinhuis KM, IJzerman NS, van der Graaf WTA, et al. Neoadjuvant systemic treatment of primary angiosarcoma. Cancers (Basel). 2020;12(8):2251.CrossRef Heinhuis KM, IJzerman NS, van der Graaf WTA, et al. Neoadjuvant systemic treatment of primary angiosarcoma. Cancers (Basel). 2020;12(8):2251.CrossRef
37.
Zurück zum Zitat Fujisawa Y, Yoshino K, Fujimura T, et al. Cutaneous angiosarcoma: the possibility of new treatment options especially for patients with large primary tumor. Front Oncol. 2018;8:46.CrossRef Fujisawa Y, Yoshino K, Fujimura T, et al. Cutaneous angiosarcoma: the possibility of new treatment options especially for patients with large primary tumor. Front Oncol. 2018;8:46.CrossRef
38.
Zurück zum Zitat Seo T, Kitamura S, Yanagi T, Ujiie H. Efficacy of a combination of paclitaxel and radiation therapy against cutaneous angiosarcoma: a single-institution retrospective study of 21 cases. J Dermatol. 2022;49(3):383–6.CrossRef Seo T, Kitamura S, Yanagi T, Ujiie H. Efficacy of a combination of paclitaxel and radiation therapy against cutaneous angiosarcoma: a single-institution retrospective study of 21 cases. J Dermatol. 2022;49(3):383–6.CrossRef
39.
Zurück zum Zitat Bi S, Zhong A, Yin X, Li J, Cen Y, Chen J. Management of cutaneous angiosarcoma: an update review. Curr Treat Options Oncol. 2022;23(2):137–54.CrossRef Bi S, Zhong A, Yin X, Li J, Cen Y, Chen J. Management of cutaneous angiosarcoma: an update review. Curr Treat Options Oncol. 2022;23(2):137–54.CrossRef
40.
Zurück zum Zitat Constantinidou A, Sauve N, Stacchiotti S, et al. Evaluation of the use and efficacy of (neo)adjuvant chemotherapy in angiosarcoma: a multicentre study. ESMO Open. 2020;5(4):e000787.CrossRef Constantinidou A, Sauve N, Stacchiotti S, et al. Evaluation of the use and efficacy of (neo)adjuvant chemotherapy in angiosarcoma: a multicentre study. ESMO Open. 2020;5(4):e000787.CrossRef
41.
Zurück zum Zitat Heinhuis KM, IJzerman NS, Koenen AM, et al. PropAngio study protocol: a neoadjuvant trial on the efficacy of propranolol monotherapy in cutaneous angiosarcoma-a proof of principle study. BMJ Open. 2020;10(9):e039449.CrossRef Heinhuis KM, IJzerman NS, Koenen AM, et al. PropAngio study protocol: a neoadjuvant trial on the efficacy of propranolol monotherapy in cutaneous angiosarcoma-a proof of principle study. BMJ Open. 2020;10(9):e039449.CrossRef
Metadaten
Titel
Prognosis of Patients with Cutaneous Angiosarcoma After Surgical Resection with Curative Intent: Is There a Difference Between the Subtypes?
verfasst von
Sophie J. M. Reijers, MD
Eva A. Huis in ’t Veld, MD
Dirk J. Grünhagen, MD, PhD
Myles J. F. Smith, MB, BCh, BAO, PhD, FRCSI
Tessa M. van Ginhoven, MD, PhD
Frits van Coevorden, MD, PhD
Winette T. A. van der Graaf, MD, PhD
Yvonne Schrage, MD, PhD
Dirk C. Strauss, MD, PhD
Rick L. M. Haas, MD, PhD
Cornelis J. Verhoef, MD, PhD
Andrew J. Hayes, MD, PhD
Winan J. van Houdt, MD, PhD
Publikationsdatum
08.10.2022
Verlag
Springer International Publishing
Erschienen in
Annals of Surgical Oncology / Ausgabe 1/2023
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-022-12601-1

Weitere Artikel der Ausgabe 1/2023

Annals of Surgical Oncology 1/2023 Zur Ausgabe

Häusliche Gewalt in der orthopädischen Notaufnahme oft nicht erkannt

28.05.2024 Häusliche Gewalt Nachrichten

In der Notaufnahme wird die Chance, Opfer von häuslicher Gewalt zu identifizieren, von Orthopäden und Orthopädinnen offenbar zu wenig genutzt. Darauf deuten die Ergebnisse einer Fragebogenstudie an der Sahlgrenska-Universität in Schweden hin.

Fehlerkultur in der Medizin – Offenheit zählt!

28.05.2024 Fehlerkultur Podcast

Darüber reden und aus Fehlern lernen, sollte das Motto in der Medizin lauten. Und zwar nicht nur im Sinne der Patientensicherheit. Eine negative Fehlerkultur kann auch die Behandelnden ernsthaft krank machen, warnt Prof. Dr. Reinhard Strametz. Ein Plädoyer und ein Leitfaden für den offenen Umgang mit kritischen Ereignissen in Medizin und Pflege.

Mehr Frauen im OP – weniger postoperative Komplikationen

21.05.2024 Allgemeine Chirurgie Nachrichten

Ein Frauenanteil von mindestens einem Drittel im ärztlichen Op.-Team war in einer großen retrospektiven Studie aus Kanada mit einer signifikanten Reduktion der postoperativen Morbidität assoziiert.

TAVI versus Klappenchirurgie: Neue Vergleichsstudie sorgt für Erstaunen

21.05.2024 TAVI Nachrichten

Bei schwerer Aortenstenose und obstruktiver KHK empfehlen die Leitlinien derzeit eine chirurgische Kombi-Behandlung aus Klappenersatz plus Bypass-OP. Diese Empfehlung wird allerdings jetzt durch eine aktuelle Studie infrage gestellt – mit überraschender Deutlichkeit.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.